BR112023002089A2 - Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4 - Google Patents
Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4Info
- Publication number
- BR112023002089A2 BR112023002089A2 BR112023002089A BR112023002089A BR112023002089A2 BR 112023002089 A2 BR112023002089 A2 BR 112023002089A2 BR 112023002089 A BR112023002089 A BR 112023002089A BR 112023002089 A BR112023002089 A BR 112023002089A BR 112023002089 A2 BR112023002089 A2 BR 112023002089A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- smarca2
- smarca4
- degradators
- pyridazine compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041033326 | 2020-08-04 | ||
| PCT/IB2021/057089 WO2022029617A1 (en) | 2020-08-04 | 2021-08-03 | 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002089A2 true BR112023002089A2 (pt) | 2023-02-28 |
Family
ID=80117730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002089A BR112023002089A2 (pt) | 2020-08-04 | 2021-08-03 | Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12570650B2 (https=) |
| EP (1) | EP4192835A4 (https=) |
| JP (1) | JP2023536504A (https=) |
| KR (1) | KR20230061349A (https=) |
| CN (1) | CN116529250A (https=) |
| AU (1) | AU2021320052A1 (https=) |
| BR (1) | BR112023002089A2 (https=) |
| CA (1) | CA3188024A1 (https=) |
| IL (1) | IL300387A (https=) |
| MX (1) | MX2023001445A (https=) |
| WO (1) | WO2022029617A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| BR112022012410A2 (pt) | 2019-12-23 | 2022-08-30 | Kymera Therapeutics Inc | Degradadores smarca e usos dos mesmos |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| WO2025196686A1 (en) * | 2024-03-20 | 2025-09-25 | Aurigene Oncology Limited | Fused bicyclic compounds as smarca2 and/or smarca4 degraders |
| CN119874808B (zh) * | 2025-01-02 | 2026-04-17 | 四川大学 | 一种靶向smarca蛋白降解的化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017518348A (ja) * | 2014-06-20 | 2017-07-06 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | Ｉｒａｋ４阻害剤としての置換インダゾール化合物 |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017011371A1 (en) * | 2015-07-10 | 2017-01-19 | Arvinas, Inc | Mdm2-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| KR20190140438A (ko) * | 2017-02-28 | 2019-12-19 | 에피자임, 인코포레이티드 | 암 치료를 위한 smarca2의 저해 |
| US20190300521A1 (en) | 2018-04-01 | 2019-10-03 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| US12371426B2 (en) | 2018-04-26 | 2025-07-29 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as SMARCA2/4 degraders |
| AU2021205326A1 (en) * | 2020-01-10 | 2022-07-21 | Amgen Inc. | SMARCA2-VHL degraders |
-
2021
- 2021-08-03 WO PCT/IB2021/057089 patent/WO2022029617A1/en not_active Ceased
- 2021-08-03 CN CN202180068383.4A patent/CN116529250A/zh active Pending
- 2021-08-03 AU AU2021320052A patent/AU2021320052A1/en active Pending
- 2021-08-03 US US18/019,721 patent/US12570650B2/en active Active
- 2021-08-03 IL IL300387A patent/IL300387A/en unknown
- 2021-08-03 CA CA3188024A patent/CA3188024A1/en active Pending
- 2021-08-03 BR BR112023002089A patent/BR112023002089A2/pt unknown
- 2021-08-03 MX MX2023001445A patent/MX2023001445A/es unknown
- 2021-08-03 KR KR1020237005345A patent/KR20230061349A/ko active Pending
- 2021-08-03 EP EP21852975.8A patent/EP4192835A4/en active Pending
- 2021-08-03 JP JP2023507923A patent/JP2023536504A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4192835A4 (en) | 2024-08-21 |
| US20240018134A1 (en) | 2024-01-18 |
| EP4192835A1 (en) | 2023-06-14 |
| JP2023536504A (ja) | 2023-08-25 |
| WO2022029617A1 (en) | 2022-02-10 |
| CN116529250A (zh) | 2023-08-01 |
| KR20230061349A (ko) | 2023-05-08 |
| MX2023001445A (es) | 2023-05-08 |
| CA3188024A1 (en) | 2022-02-10 |
| AU2021320052A1 (en) | 2023-03-23 |
| US12570650B2 (en) | 2026-03-10 |
| IL300387A (en) | 2023-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023002089A2 (pt) | Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4 | |
| JOP20230318A1 (ar) | مشتقات تترا هيدرو – إيميدازوبيريدين كمعدِّلات مناعية pd-l1 | |
| ZA202403923B (en) | Heterocyclic compounds as immunomodulators | |
| WO2021262826A3 (en) | 1'-cyano nucleoside analogs and uses thereof | |
| MX2021006841A (es) | Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?. | |
| BR112023016299A2 (pt) | Composições e métodos para inibir kras | |
| MY209609A (en) | Immunomodulators, compositions and methods thereof | |
| EA202191801A1 (ru) | Гетероциклические ингибиторы mat2a и способы применения для лечения рака | |
| BR112022004424A2 (pt) | Pró-fármacos antivirais e formulações dos mesmos | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| DK1427708T3 (da) | Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| BR112018007128A2 (pt) | compostos para a inibição de câncer e epigênese | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| ZA202301066B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
| MX2021013602A (es) | Inhibidores de jak. | |
| BR112018067552A2 (pt) | inibidores de cinase | |
| MX2021003901A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica |